CSPC Pharmaceutical Group Nachrichten

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• 
  Big Pharma Is Pouring Billions Into China’s Biotechs (öffnet in neuem Tab)

  Barrons.com · 14.09.2026

• 
  The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight (öffnet in neuem Tab)

  PR Newswire · 01.06.2026

• 
  CSPC’s SYS6051 Trial Approval Adds New Angle To Valuation Story (öffnet in neuem Tab)

  Simply Wall St. · 22.04.2026

• 
  2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation (öffnet in neuem Tab)

  PR Newswire · 22.04.2026

• 
  Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint (öffnet in neuem Tab)

  PR Newswire · 01.04.2026

• 
  How Regulatory Approval for CSPC Pharmaceutical’s First C5 siRNA Therapy (SEHK:1093) Has Changed Its Investment Story (öffnet in neuem Tab)

  Simply Wall St. · 07.11.2025

• 
  Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates (öffnet in neuem Tab)

  GlobeNewswire · 04.11.2025

• 
  How Dual U.S. and China Trial Approvals for SYH2070 Could Shape CSPC (SEHK:1093) Investors' Outlook (öffnet in neuem Tab)

  Simply Wall St. · 13.10.2025